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Growth hormone receptor abundance in tibial growth plates factor-I (GH/IGF-I) axis is one of many factors that may
of uremic rats: GH/IGF-I treatment. contribute to this growth retardation. In particular, CRF
Background. Children with chronic renal failure (CRF) ex- is associated with normal or elevated serum levels of
hibit growth retardation and a disturbed growth hormone/insu-
GH and normal or decreased serum levels of IGF-I de-lin-like growth factor-I (GH/IGF-I) axis. Treatment of children
pending on the state of renal failure, suggesting a statewith CRF with GH or GH/IGF-I can partially restore linear
of GH insensitivity in target organs [1–6]. Treatment ofgrowth. The molecular basis for decreased longitudinal growth
is not known but may involve an impaired action of GH. CRF children with recombinant human GH (rhGH) can
Methods. We used the growth-retarded uremic rat model to partially restore linear growth, suggesting that the insen-
determine the abundance and distribution of GH receptors sitivity to endogenous GH can be overcome [7–11]. Rats
(GHRs) in the tibial epiphyseal growth plate and the influence with experimental uremia are also growth retarded, andof GH, IGF-I, or combined GH/IGF-I treatment. Pair-fed rats
studies have shown varying degrees of restoration ofwere used as the control.
linear growth with GH [12–20], IGF-I, or combinationsResults. While all treatment regimes increased body length
and weight in both rat groups, only GH/IGF-I treatment in- of GH/IGF-I treatment [21–23].
creased the total growth plate width. This involved an increase The molecular basis for the decrease in longitudinal
in cell number in the hypertrophic zone, which could also growth seen in CRF is not clearly understood. GH is a
be induced by IGF-I alone. Immunohistochemical analysis major regulator of bone growth [24–27]. GH is likely to
showed that uremic rats had decreased abundance of GHRs
act directly on GH receptors (GHRs) on growth-platein the proliferative zone, and only GH/IGF-I therapy could
chondrocytes [28] and, in association with local produc-overcome this decrease. These data thus suggest that growth
tion of IGF-I, increases growth plate width [29]. Uremicretardation in uremic rats is, at least in part, due to a decrease
in GHR abundance in chondrocytes of the proliferative zone rats show a disorganized tibial epiphyseal growth plate,
of the tibial growth plate. This decreased GHR abundance can which may be slightly wider or narrower than normal
be overcome by combined GH/IGF-I therapy, thus enhancing controls [13, 22]. Treatment with GH results in expansion
generation and proliferation of hypertrophic zone chondro- of the growth plate width, which may selectively involvecytes and increasing growth-plate width.
specific zones [17, 23]. We therefore hypothesized thatConclusion. These studies point to a mechanism for the
retarded linear bone growth in uremia may be due to agrowth retardation seen in children with CRF, and suggest that
change in GHR distribution and/or abundance in thecombined GH/IGF-I treatment may provide more effective
therapy for these patients than GH alone. growth plate. Furthermore, we predicted that treatment
with GH or IGF-I or combined GH/IGF-I may modulate
receptor abundance, thus providing a potential mecha-
nism for growth-promoting effects. In this study, we haveChronic renal failure (CRF) in children is associated
used the uremic rat model to characterize, by immuno-with severe growth failure. Recent studies have shown
histochemistry, the distribution and abundance of GHRsthat a perturbed growth hormone/insulin-like growth
in the tibial epiphyseal growth plate. We have then exam-
ined the effect of GH, IGF-I, and GH/IGF-I therapy on
Key words: chronic renal failure, development, hypertrophy, growth abundance and distribution of GHRs in the tibial growth
retardation, bone growth, epiphyseal growth plate, growth hormone, plate of the uremic rat.insulin-like growth factor-I.
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experiments. One week prior to the study, the animals as a negative control (1:100). The Vectastain ABC kit
(Vector Laboratories Inc., Burlingame, CA, USA) waswere kept in single cages at constant room temperature
(248C) and humidity (70%) on a 12-hour on/off light used for to detect bound primary antibody. Briefly, sec-
tions were dewaxed in Histolene (Riverstone, New Southcycle. The animals had free access to food (Altro min
C 1000 diet; Altromin Co., Lage/Lippe, Germany) and Wales, Australia), rehydrated by passage through graded
ethanol and ultrapure water (Liquipure Continental Wa-deionized water. The diet contained 13800 kJ/kg, 0.95%
calcium, 0.8% phosphorus, 500 IU/kg vitamin D3, and ter System, Melbourne, Victoria, Australia), and incu-
bated in H2O2 in PBS (pH 7.4) to quench endogenous18% protein (wt/wt). The animals were randomized to
the experimental groups according to their body weight. peroxidase activity, and nonspecific protein binding was
eliminated by incubation with horse serum. SectionsThe animals were subjected to two-stage subtotal ne-
phrectomy (NX), as described previously [13, 30]. Five were then incubated with (1) diluted primary antibody
(mAb 263, mAb 7), followed by (2) diluted biotinylateddays after subtotal NX of the left kidney, when the ani-
mals had a mean body weight of 132 g, the contralateral second antibody (antimouse), and then (3) Vectastain
ABC reagent. Following the diaminobenzidine (DAB)/kidney was removed, and uremia resulted. Control ani-
mals were sham operated (renal decapsulation). Uremic peroxidase reaction, sections were counterstained with
hematoxylin and eosin, dehydrated in graded ethanol,animals had free access to food and water, whereas the
control groups were pair fed to the uremic group, as cleared in histolene (Riverstone), and mounted under
DPX (BDH, Dorset, UK).described previously [21]. Pair feeding started after the
first stage of operation. The duration of uremia in all
Analysisexperiments was 10 days.
In vivo measurement of body length and weight. Body
Experimental protocol length and weight were measured during the afternoon
in nonfasting animals. Nose-to-tail tip distances wereThe uremic animals and the pair-fed control animals
were randomized into four groups (N 5 4 animals/treat- measured in anesthetized animals under complete mus-
cle relaxation as described previously [13, 30]. The in-ment group). Group 1 received vehicle twice daily subcu-
taneously. Group 2 was treated with 7.5 IU rhGH/kg/day crease in body weight and length in both uremic and
pair-fed animals was used for analysis.twice daily subcutaneously. Group 3 was treated with
3 mg rhIGF-I/kg/day twice daily subcutaneously, and Growth plate width analysis. Total growth plate and
regional [proliferative (P) and hypertrophic (H)] growthgroup 4 received a combination of rhGH and rhIGF-I
in the doses indicated previously in this article. Recombi- plate width were analyzed using the microcomputer im-
aging device (MCID) M4 image analyzer (Imaging Re-nant human GH (Genotropin) and rhIGF-I (CH/B/
60229-51) was a gift of Pharmacia and Upjohn Company search Inc., St. Catherines, Canada). Total growth-plate
width was measured as the distance from the bone matrix(Stockholm, Sweden). Hormonal and vehicle injection
were started after the second operation for subtotal NX. in the reserve zone to bone matrix in between the zone
of calcifying cartilage and developing trabeculae of theThe duration of treatment was 10 days.
metaphysis. P zone width was taken as the distance from
Processing of tissue the bone matrix in the reserve zone to the distal border
of the last line of P cells prior to clear H change. H zoneTibias were excised, broken midshaft, trimmed of ex-
cess tissue, and placed in placed in 10% formalin in width was taken as the distance from this line to the
mature edge of the growth plate. Following calibrationphosphate-buffered saline (PBS; Oxiod, Basingstoke,
Hampshire, UK) for 24 hours at 48C. Tibias were then of the MCID system, 12 different measurements (mm)
for each growth plate or growth plate zone were taken,decalcified in 5% formic acid at 48C for up to 20 days.
Following decalcification, tibias were split in the midline and a mean width was calculated.
Cell number. Cell numbers within the P and H zonessagittal plane and processed through graded ethanol,
cleared in two changes of xylene, and infiltrated with of tibial epiphyseal growth plates were counted blind
from three different microscopic fields per growth plate,paraffin wax. Six micrometer sections were cut, mounted
on aminoalkylsilane-coated slides [31], and baked over- using a grid to maintain standard area counted. An aver-
age of the three fields was calculated, and data were thennight at 378C.
expressed as average cell numbers for each treatment
Immunohistochemistry group.
Growth hormone receptor-positive chondrocyte identi-Epiphyseal growth plate sections were subjected to
immunohistochemistry as previously described [32] with fication and distribution analysis. GHR-positive chon-
drocytes of tibial epiphyseal growth plates, indicated bymodifications as follows: Monoclonal antibody 263 (mAb
263) [33] was used at a concentration of 1:100 to detect a dark-brown peroxidase reaction, were counted by a
blinded observer in both the P or H zones. Three differ-GHR. Monoclonal antibody 7 (mAb 7) [33] was used
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ent microscopic fields per growth plate were assessed
for GHR-positive cells using a grid to maintain a stan-
dard area, which was analyzed. Data were expressed as
the percentage of cells that were GHR positive per the
total number of cells per zone.
Statistical analysis
Data are reported as mean 6 SD. For comparison of
length gain and weight gain between groups, a two-way
analysis of variance (ANOVA) was performed followed
by all pair-wise multiple comparison (Student–Newman–
Keuls method). Growth plate measurements were ana-
lyzed by a one-way ANOVA followed by a Newman–
Kuels Multiple Comparison test. P , 0.05 was accepted
as being statistically significant. All analyses were under-
taken using Prism GraphPad software (San Diego, CA,
USA).
RESULTS
Surrogate markers for renal function measured at sac-
rifice indicated a significant impairment of glomerular
filtration rate. Serum creatinine values were (mean and
range) 1.1 (0.7 to 1.3) mg/dL in uremic animals and 0.3
(0.2 to 0.3) mg/dL in pair-fed controls. GH and IGF-I
did not significantly influence those values.
Fig. 1. Effect of growth hormone (GH), insulin-like growth factor-IGH, IGF-I, or GH/IGF-I treatment increases the
(IGF-I), or combined GH/IGF-I treatment for 12 days on weight gainweight and length of uremic and pair-fed rats and length gain in uremic ( ) or pair-fed (j) rats. (A) Weight gain in
uremic or pair-fed rats treated with vehicle, IGF-I, GH, or GH/IGF-I.Figure 1A represents the analysis of total weight gain
*P , 0.001 vs. vehicle-treated uremic rats; ¥ P , 0.01 vs. IGF-I–treatedof both uremic and pair-fed rat groups treated with either uremic rats; rP , 0.001 vs. pair-fed vehicle-treated rats; #P , 0.001 vs.
vehicle (saline), GH, IGF-I, or combined GH/IGF-I. The vehicle-treated pair-fed rats; jP , 0.05 vs. IGF-I treated pair-fed rats,
dP , 0.01 vs. GH/IGF-I treated pair-fed rats. (B) Length gain in uremicadministration of GH, IGF-I, or GH/IGF-I to uremic
( ) or pair-fed (j) rats treated with vehicle, IGF-I, GH, or GH/IGF-I.
rats resulted in a significant weight gain (P , 0.001), *P , 0.001 compared with respective control groups, that is, uremic/
vehicle-treated or pair-fed/vehicle-treated rats. Data are mean 6 SD.with GH or GH/IGF-I being more effective than IGF-I
(P , 0.01). No additive effect of GH and IGF-I in combi-
nation was seen in uremic animals compared with GH
alone. In the case of pair-fed rats, only GH was effective
treated as previously described, were not significantlyalone (P , 0.001), but an additive effect of the combina-
different in their body length gain when compared withtion of GH/IGF-I was seen (P , 0.001). The weight gain
their respective pair-fed, treated rat group.for uremic rats either saline treated, IGF-I treated, or
Cumulative food intake for the uremic rats, and thusGH/IGF-I treated was significantly different to their
pair-fed rats, was 142 6 12 g, and this volume of foodequivalent pair-fed group (P , 0.001, P , 0.05, P ,
intake did not significantly alter with hormonal treat-0.01, respectively). In contrast, GH-treated uremic rats
ment.gained weight to the same extent as GH-treated pair-
fed rats.
Tibial epiphyseal growth-plate widths are increased byFigure 1B summarizes the analysis of body length gain
combined GH/IGF-I treatmentof both uremic and pair-fed rat groups treated with either
The total width of tibial epiphyseal growth plates fromvehicle, GH, IGF-I, or GH/IGF-I. Treatment of both
uremic rats was not significantly different to pair-fed ratsuremic and pair-fed rats with GH, IGF-I, or combined
(Fig. 2A). Only GH/IGF-I treatment of both uremic orGH/IGF-I resulted in a significant gain in body length
pair-fed rats resulted in a significant increase in totalwhen compared with their respective control groups (P ,
growth plate width when compared with their corre-0.001). However, no difference was seen between the
sponding saline treated rat groups (P , 0.01, P , 0.001,effect of GH or IGF-I alone or in combination in either
uremic or pair-fed animals. Uremic rats, including those respectively), but growth-plate width of uremic GH/IGF-
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rats treated with GH/IGF-I showed an increase in P zone
width when compared with untreated uremic rats (P ,
0.05). No differences in P zone widths were seen within
the pair-fed rat groups under any treatment regime com-
pared with saline-treated, pair-fed rats (Fig. 2B), al-
though the P zone width of IGF-I–treated pair-fed rats
was significantly wider compared with IGF-I–treated
uremic rats (P , 0.05).
Hypertrophic zone widths of tibial growth plates were
increased following GH/IGF-I therapy for both uremic
and pair-fed rats when compared to uremic-or pair-fed
vehicle-treated rats, respectively (P , 0.05; Fig. 2C). In
contrast, there was no difference in the H zone width
between uremic and pair-fed groups for all treatment
regimes.
GH/IGF-I treatment increases chondrocyte cell
numbers of the H zone in tibial epiphyseal growth
plates of both uremic and pair-fed rats
Chondrocyte cell numbers within both P and H zones
of tibial growth plates from all experimental rat groups
were analyzed (Fig. 3). Uremic rats under any treatment
regime did not show a significant change in P zone chon-
drocyte numbers. In contrast, only GH treatment of
pair-fed rats resulted in a significant increase in P zone
chondrocyte number when compared with GH/IGF-I
treatment of pair-fed rats (P , 0.05). A comparison of
uremic rats with pair-fed rats under the same treatment
regime did not reveal any significant differences in P
zone chondrocyte number.
In uremic rats, either IGF-I or GH/IGF-I treatment
led to an increase in H cell numbers of the tibial growth
plate when compared with vehicle-treated uremic rats
(P , 0.001 and P , 0.01, respectively; Fig. 3B). IGF-
treated uremic rats had significantly more H cells when
compared with both GH-treated and GH/IGF-I–treated
uremic rats (P , 0.001). Furthermore, IGF-I–treated
uremic rats had significantly more H cells when com-
pared with pair-fed rats treated with vehicle, GH, IGF-I,
or GH/IGF-I (P , 0.001). Only GH/IGF-I treatment ofFig. 2. GH/IGF-I treatment of uremic ( ) and pair-fed (j) rats in-
creases total growth-plate width. (A) Total growth-plate width is in- pair-fed rats caused an increase in H chondrocyte num-
creased by GH/IGF-I treatment of uremic and pair-fed rats. rP , 0.01 ber when compared with vehicle-treated pair-fed rats
vs. uremic vehicle-treated rats; *P , 0.001 vs. pair-fed vehicle-treated
(P , 0.05).rats; ¥ P , 0.01 vs. GH/IGF-I-treated pair-fed rats. (B) The P zone
width of tibial epiphyseal growth plates of uremic rats is increased by
GH/IGF-I treatment. dP , 0.05 vs. vehicle-treated uremic rats; *P , GHR abundance in tibial epiphyseal growth plates is
0.05 vs. IGF-I-treated uremic rats. (C) The H zone width of tibial decreased in uremia, but increased by
epiphyseal growth plates of uremic rats is increased by GH/IGF-I treat-
GH/IGF-I treatmentment. dP , 0.05 vs. vehicle-treated uremic or pair-fed rats, respectively.
Data are mean 6 SD. Growth hormone receptor abundance in tibial epiphy-
seal growth plate chondrocytes was assessed by immuno-
histochemical staining [Fig. 4A (i), (ii)], and the results
are expressed as the percentage of cells that are GHRI–treated rats was significantly less than pair-fed GH/
positive. Firstly, tibial growth plate GHR abundance inIGF-I–treated uremic rats (P , 0.01).
uremic rats was decreased when compared with growthTibial growth-plate widths were further analyzed by
plates from pair-fed rats (P , 0.05; Fig. 4B). This de-assessing regional widths, within the P (Fig. 2B) or H
zones (Fig. 2C), of each rat treatment group. Only uremic crease in GHR abundance was seen in the P zone only
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fected by any treatment regime for either uremic or pair-
fed rat groups (Fig. 4C).
DISCUSSION
We have shown in this study that combined GH and
IGF-I therapy overcomes the growth failure of uremia,
and that this involves expansion of growth plate width
and cell number in the H zone. While such findings have
been described previously by ourselves and others, the
present study provides a likely mechanism for these
changes. To our knowledge, we demonstrate for the first
time that uremic rats show a decreased abundance of
GHR-positive chondrocytes in the P zone of the tibial
epiphyseal growth plate. Furthermore, and most signifi-
cantly, we show that combined therapy with GH and
IGF-I in these uremic rats results in an increased abun-
dance of GHRs in the P zone of the growth plate, thus
reversing the adverse effects of uremia on GH-respon-
sive chondrocytes and leading to growth plate expansion
in response to combined GH and IGF-I.
The reduction in GHR abundance in P zone chondro-
cytes in uremia is clearly a specific effect of uremia, since
it is not seen in pair-fed animals with a similarly reduced
food intake. Uremia has been previously shown to be
associated with reduced GH binding to liver membranes
[34] and associated reduction in hepatic GHR mRNA
expression [35]. Although we did not examine GHRFig. 3. GH/IGF-I treatment of uremic ( ) or pair-fed (j) rats in-
creases H cell number of tibial epiphyseal growth plates. (A) Analysis mRNA in the present study, it is likely that this would
of P zone chondrocyte cell number following treatment with vehicle, be similarly reduced in the growth plate to account forGH, IGF-I, or GH/IGF-I. Only GH treatment of pair-fed rats results
reduced GHR protein abundance. The in vitro findingsin an increase in P zone chondrocytes. dP , 0.05 vs. GH/IGF-I-treated
pair-fed rats. (B) Analysis of H zone chondrocyte cell number following of Mak and Pak showing that chondrocytes from uremic
treatment with vehicle, GH, IGF-I, or GH/IGF-I. rP , 0.01 vs. vehicle- rats show “end-organ resistance” to GH and IGF-I aretreated uremic rats; dP , 0.05 vs. vehicle-treated pair-fed rats; *P ,
consistent with reduced abundance of GHR and possibly0.001 vs. vehicle-treated uremic rats; #P , 0.001 vs. GH-treated and
GH/IGF-I-treated uremic rats; jP , 0.001 vs. vehicle-, GH-, IGF-I–, insulin-like growth factor-I receptor (IGF-IR) [36].
and GH/IGF-I–treated pair-fed rats. Data are mean 6 SD. Although there are significant data on the in vivo
growth and weight-enhancing effects of GH and IGF-I
alone or together in growth-retarded uremic rats [12–23],
the underlying mechanisms of their effects have re-and was not overcome by individual GH or IGF-I treat-
mained unclear. Our finding that the combination of GHment of uremic rats. In contrast, the GHR abundance
and IGF-I is more effective on both weight gain andin the P zone of GH/IGF-I–treated uremic rats was sig-
growth plate expansion than GH or IGF-I alone is consis-
nificantly increased when compared with uremic vehicle-
tent with findings of Hazel et al [22], who showed similar
treated rats (P , 0.001). GH/IGF-I therapy of uremic effects on weight and metabolic changes.
rats was able to restore GHR abundance in the P zone The interpretation of the growth data in our present
to levels seen in vehicle-, GH-, IGF-I–, or GH/IGF- study is, however, limited because the study was designed
treated pair-fed rats. GH- or IGF-I–treated uremic rats for a semiquantitative analysis of GHR expression. In
also had reduced GHR abundance in P zone chondro- contrast to earlier experiments [21, 23], the duration of
cytes when compared with their corresponding pair-fed the experiment was reduced (but long enough to regulate
treated rats (P , 0.01, P , 0.05, respectively). GH treat- the GHR by hormonal treatment). The treatment dose
ment of pair-fed rats also led to an increase in GHR of GH and of IGF-I was suboptimal, and the number of
abundance in the P zone when compared with vehicle- animals per group was smaller. Our earlier experiment
treated pair-fed rats (P , 0.05). with maximally effective doses of GH and of IGF-I dem-
Growth hormone receptor abundance within the H onstrated an additive effect of GH and of IGF-I [23].
In the present study, we used smaller doses of GH andregion of tibial growth plates was not significantly af-
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Fig. 4. Growth hormone receptor (GHR) abundance in tibial epiphy-
seal growth plates is decreased in uremia, but increased by GH/IGF-I
treatment. (A) Representative light field views of immunohistochemi-
cal staining for GHRs (mAb 263) in tibial epiphyseal growth plate of
(i) uremic and (ii) pair-fed vehicle-treated rats. GHR-positive cells
are stained brown. (iii) Tibial epiphyseal growth plate from pair-fed
vehicle-treated rats stained with MAb 7 control antibody. Abbrevia-
tions are: P, P zone; H, H zone. Bar 5 50 mm. (B) GHR abundance
in P zone chondrocytes. Data are expressed as the percentage of cells
that was GHR positive per the total number of cells per P zone. dP ,
0.05 vs. vehicle treated pair-fed rats; *P , 0.001 vs. vehicle-treated
uremic rats; rP , 0.01 vs. GH-treated pair-fed rats; #P , 0.05 vs. IGF-
I-treated pair-fed rats; dP , 0.05 vs. vehicle-treated pair-fed rats. (C)
GHR abundance in H zone chondrocytes. Data are expressed as the
percentage of cells that were GHR positive per the total number of
cells per H zone. Data are mean 6 SD.
IGF-I, intending not to maximally up-regulate the GHR growth plate width, nose-tail length, and weight gain.
This provides further strong support for our originalby either GH or IGF-I alone. Our results demonstrate
that the combination of GH and IGF-I was more effec- hypothesis that the mechanisms of action of these pep-
tides on linear growth might be via regulation of growthtive at enhancing GHR expression in the tibial growth
plate than the treatment with one of the hormones alone. plate GHRs. The initial finding that the growth failure
of uremia was associated with reduced expression ofThis is consistent with the earlier results [23]. However,
we cannot exclude that a higher dose of GH or of IGF-I tibial GHRs also, of course, pointed to this possibility.
In contrast, pair-fed animals maintained higher levels ofwould also have had a greater effect on the GHR expres-
sion. For logistic reasons, we could not perform dose- GHR abundance, showing no change in response to GH/
IGF-I treatment, in spite of similar linear growth andresponse experiments.
The effect of GH/IGF-I to increase GHR abundance weight responses. Furthermore, in pair-fed animals, in-
creased growth plate width in response to GH and IGF-Iin uremic rats was consistent with its positive effects on
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was limited to the H zones. In contrast, in uremic rats we suggest that an increase in GHR-responsive P zone
chondrocytes would lead to an increase in the numbertreated with GH and IGF-I, both P and H zones ex-
panded, in concert with the increased GHR expression of differentiated H zone chondrocytes. The findings of
Hanna et al are also in support of these results, in whichin the P zone. These findings clearly suggest that mecha-
nisms of growth regulation via the GH/IGF-I axis in they described an increase in IGF-I messenger RNA in
the P zone in response to GH therapy in uremic ratsuremia are distinct from those in nutrition, specifically
involving regulation of GH action via control of growth [17]. This again would be expected in response to direct
local actions of GH and would be further enhanced byplate GHR abundance.
Our use of sham-operated pair-fed animals as controls GHR up-regulation. It is once again consistent with the
“dual effector” theory, in which proliferating chondro-for uremic animals clearly allowed us to distinguish the
effects of uremia from the effects of inadequate nutrition cytes synthesize IGF-I in response to GH and enhance
H bone expansion. Consistent with this, IGF-I treatmentper se. Uremia has a distinct effect on the metaphyseal
width of long bones, particularly the H zone, an effect of uremic rats increased H zone chondrocyte cell num-
ber, although it did not lead to an increase in growth platedependent on duration and severity of uremia [13, 23,
37]. Chondrocyte cell turnover per column is reduced, cell width, suggesting that factors other than chondrocyte
number, such as extracellular matrix production, contrib-with a longer duration of the H phase and reduced cellu-
lar advance velocity and cartilage resorption, leading to ute to growth plate width. An alternative model pro-
posed by Hunziker, Wagner, and Zapf [40], whereby thean accumulation of cartilage cells at the H zone [37].
These processes are dependent on the severity of uremia, role of GH and IGF-I overlap with respect to differentia-
tion and proliferation, would also be consistent with ourthe duration of the experiments, and the age of the ani-
mals, explaining why differing findings on the height of findings.
The dual role of GH and IGF-I in growth plate matura-the growth plate in uremia have been reported [13, 23,
37]. In the present experiments, serum creatinine and tion and expansion is thus emphasized. It is not clear
whether locally synthesized IGF can itself induce up-urea levels at sacrifice indicated a significant reduction
of renal function in uremic animals compared with pair- regulation of GHRs in vivo. Our earlier in vitro studies
using cultured rat growth plate chondrocytes showed afed controls. According to our model, uremia is even
higher shortly after the second stage of subtotal NX. In positive effect of IGF-I on GHR abundance [41], while
our recent study showed no effect [42]. In contrast, recentearlier experiments, we observed within three days an
increase of serum creatinine to about 1.6 mg/dL and of in vitro findings in bone cells suggest the converse [43].
Certainly, our current in vivo findings do raise the possi-urea to more than 200 mg/dL [23]. As in earlier experi-
ments, GH and IGF-I did not significantly influence renal bility that IGF-I may play a role in up-regulating the
tibial GHR, since only GH/IGF-I, and not GH or IGF-Ifunction [23].
In our short-term experiments, the growth plate width alone, significantly increase GHR expression in the ure-
mic growth plate.did not differ between uremic and pair-fed control ani-
mals, probably because of the short duration of uremia. In spite of these findings that GHR expression and
growth plate width are only increased by GH and IGFIn contrast to our previous results [23], GH or IGF-I
alone did not lead to increased growth plate width, prob- in combination, it is clear that both GH and IGF-I alone
are able to increase overall linear growth and weightably because of the lower doses used and shorter experi-
mental duration; they were, however, effective in combi- gain. In the case of IGF-I, we found that IGF-I therapy
increases H zone chondrocyte numbers in uremic rats,nation. The increase of the H zone width following
combined treatment with GH and IGF-I may be inter- consistent with the notion that expanded P zone clones
are IGF-I responsive [38]. Clearly, there may be a num-preted in the light of recent kinetic data [37]. Hormonal
treatment might increase cell proliferation and also the ber of other systemic or local mechanisms whereby GH
or IGF-I alone increase linear growth and weight gain.conversion from proliferating cells into H cells, but not
the resorption of H cells to the same degree. Our finding of decreased GHRs in rat tibial growth
plates thus suggests that the growth retardation exhibitedThe finding that GHR abundance was increased in
the P and not the more mature H zone in response to in children with CRF may be related to a similar reduc-
tion in GHR abundance, resulting in reduced sensitivityGH/IGF-I is consistent with the original “dual effector”
theory [38, 39], in which GH is responsible for differenti- to endogenous GH. Consistent with this notion is the
finding that children with CRF have low circulating levelsation of the less mature chondrocytes in the growth plate,
in this case inducing further GHR expression and en- of GH-binding protein, a marker for tissue GHR [44].
Up-regulation of P zone chondrocyte GHR expressionhanced GH sensitivity. Our data showing an increase
in growth plate width by GH/IGF-I treatment and the in response to combined GH/IGF-I therapy is thus likely
to enhance GH sensitivity and accounts for growth plateresultant increase in H zone chondrocyte number only
further support the “dual effector” theory. Specifically, expansion, linear growth, and weight gain. Hence, these
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effects of exogenous rat growth hormone therapy on growth ofstudies not only suggest that combined GH/IGF-I treat-
uremic rats fed an 8% protein diet. Pediatr Res 26:204–207, 1989
ment of CRF children may be a more appropriate ther- 16. Arnold WC, Shirkery B, Frindik P, Ellis E: Effect of growth
hormone on kidney growth and glomerula structure. Pediatrapy than GH or IGF-I alone, but also provide a mecha-
Nephrol 5:529–532, 1991nism for these observations.
17. Hanna JD, Santos F, Foreman JW, Chan JCM, Han VKM: Insu-
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